Major Depressive DisorderNCT06443242
Efficacy and Safety of Low-dose Laser Acupuncture on Treating Insomnia Associated With Major Depressive Disorder
A study testing Low-Dose Laser Acupuncture (LLA) in people with Major Depressive Disorder and Insomnia, run by Mohammad Farris Iman Leong Bin Abdullah.
Trial summary
The goal of this randomized controlled trial is to assess the efficacy and safety of low-dose laser acupuncture (LLA) in alleviating insomnia symptoms among patients suffering from major depressive disorder. The study seeks to answer the following questions: 1. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Major Depressive Disorder, Insomnia
- What is being tested?
- Low-Dose Laser Acupuncture (LLA)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2025to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Inpatients with a diagnosis of major depressive disorder (diagnosed according to the relevant diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders-V).
- Male or female, 18 to 60 years of age.
- Participants complaining of insomnia at initial screening.
- PSQI score over 7.
- HAMD score between 20 and 35.
- No use of hypnotic medication or acupuncture treatment within the last month.
Show all 9Show fewer
- No cognitive or communication disorders.
- Willingness to accept random group assignment and sign an informed consent form.
- Those who have been on stable dose of antidepressant for at least the most recent two weeks and willing to maintain on the same dosage throughout the study.
Who cannot join
- Individuals with a marked tendency towards suicide, as assessed by a specialist;
- Individuals previously diagnosed with schizophrenia, bipolar disorder, or other psychiatric disorders;
- Individuals with severe alcohol or drug abuse issues;
- Individuals with liver or kidney dysfunction, or with uncontrollable tumors or significant cerebrovascular diseases;
- Women who are pregnant or breastfeeding;
- Individuals likely to have poor compliance or who are fearful of acupuncture treatment.
About this study
Official title: Efficacy and Safety of Low-dose Laser Acupuncture on Treating Insomnia Associated With Major Depressive Disorder: A Randomised Controlled Trial
The goal of this randomized controlled trial is to assess the efficacy and safety of low-dose laser acupuncture (LLA) in alleviating insomnia symptoms among patients suffering from major depressive disorder.
The study seeks to answer the following questions:
Read more
- How effective is LLA in alleviating insomnia symptoms as compare with SLA and control subjects among patients with major depressive disorder across pre-treatment, mid-treatment and post-treatment assessment?
- How effective is LLA in alleviating depression symptoms as compare with SLA and control subjects among patients with major depressive disorder across pre-treatment, post-treatment and follow-up assessment?
- What role do CORT and 5-HT play in the co-occurrence and progression of insomnia and major depressive disorder, and how does LLA act on these mechanisms to provide relief?
- How does the safety and acceptability of LLA compare to traditional acupuncture in terms of eliminating discomfort and potential side effects? Researchers will compare the effects of LLA with sham laser acupuncture (SLA) and standard medication treatments to evaluate its efficacy and safety.
Participants involved in this study will:
Undergo 30 treatment sessions with LLA or SLA, five times a week for six weeks. Continue their usual pharmacological treatments for major depressive disorder. Participants will undergo comprehensive assessments at key points: pre-treatment, immediately post-treatment, and 12 weeks post-treatment. These evaluations will measure sleep quality and severity of insomnia indices, levels of depression and anxiety, and blood levels of CORT and 5-HT to assess the impact of LLA on insomnia symptoms and biochemical markers. Additionally, participant acceptance and the safety of the treatment will be monitored, including recording any adverse events and medication usage, to determine the effectiveness and safety of LLA in treating insomnia associated with major depressive disorder.
By focusing on these elements, the study aims to provide clear, actionable insights into the benefits and risks of LLA as a treatment option for insomnia associated with major depressive disorder, enhancing the current treatment landscape and patient outcomes.
Read the detailed description
This randomised controlled trial aims to explore the therapeutic potential of low-dose laser acupuncture (LLA) for treating insomnia in patients diagnosed with major depressive disorder. The study will investigate the physiological and psychological impacts of LLA in comparison with sham laser acupuncture (SLA) and standard pharmacological therapies.
Intervention Details:
LLA involves the application of a low-level laser to specific acupoints known to affect sleep and mood regulation. The technique mimics traditional acupuncture but uses laser light to stimulate these points without physical penetration of the skin, offering a non-invasive alternative with potentially fewer adverse effects. The primary acupoints targeted in this study include Baihui (GV20), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), and Taichong (LR3).
Study Phases:
The study will be structured into three key phases: pre-treatment, immediately post-treatment, and 12 weeks post-treatment. During the pre-treatment phase, baseline evaluations will be conducted to establish initial levels of insomnia and depressive symptoms in participants. The treatment phase will follow, lasting six weeks, with participants receiving five sessions per week. Subsequent assessments will occur immediately post-treatment to evaluate the immediate effects of the interventions, and again at 12 weeks post-treatment to assess the long-term outcomes.
Research Focus:
The study will particularly focus on the effectiveness of LLA in improving sleep quality as measured by validated scales and objective assessments like actigraphy, which monitors sleep-wake patterns. Additionally, the research will assess changes in psychological state and biochemical markers, which are critical in understanding the interaction between sleep disorders and depression. These measures will help ascertain whether LLA can alter the physiological pathways typically disrupted in major depressive disorder, potentially offering a new avenue for treatment that could complement or reduce the need for pharmacological intervention.
Innovation and Potential Impact:
By integrating a novel, non-invasive method such as LLA, the study could significantly impact the treatment strategies for insomnia in the context of major depressive disorder. This approach not only aims to reduce symptoms but also to enhance overall treatment tolerance and patient adherence, addressing key challenges in managing these interlinked conditions.
- Conditions
- Major Depressive Disorder, Insomnia
- Being tested
- Low-Dose Laser Acupuncture (LLA), Sham Laser Acupuncture (SLA)
- Medical subject headings
- Depressive Disorder, Major, Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low-Dose Laser Acupuncture (LLA)Device
The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep.
Sham Laser Acupuncture (SLA)Device
Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment.
| Study group | Role | What they receive |
|---|---|---|
| Low-Dose Laser Acupuncture (LLA) Group | Experimental | In the Low-Dose Laser Acupuncture (LLA) group, participants receive treatments using the xS-998D06 semiconductor laser acupoint therapeutic device from Nanjing Xiaosong Medical Instruments. This device operates at a wavelength of 780 nm and an output power of 5 mW. Each 20-minute session involves securing the device's probe to specific acupoints (Baihui, Yintang, Anmian, Shenmen, Neiguan, Sanyinjiao, and Taichong) using medical tape. Treatments occur daily for 5 consecutive days each week, with a two-day break, over a 6-week period. All participants, regardless of group assignment, will maintain their regular antidepressant regimen (patients with only one type of antidepressant, such as selective serotonin reuptake inhibitor [SSRI] or serotonin noradrenaline reuptake inhibitor [SNRI] or mirtazapine). Receives: Device: Low-Dose Laser Acupuncture (LLA) |
| Sham Laser Acupuncture (SLA) Group | Sham comparator | Participants in the Sham Laser Acupuncture (SLA) group undergo a sham treatment involving the same procedure and acupoint targeting as the LLA group. The difference lies in the instrument probe being fixed to the acupoint but emitting a dummy laser, simulating the acupuncture experience without actual laser emission. All participants, regardless of group assignment, will maintain their regular antidepressant regimen (patients with only one type of antidepressant, such as selective serotonin reuptake inhibitor [SSRI] or serotonin noradrenaline reuptake inhibitor [SNRI] or mirtazapine). Receives: Device: Sham Laser Acupuncture (SLA) |
| Control Group | No intervention | The control group, which serves as a non-intervention comparison, will continue their standard treatment regimen (patients with only one type of antidepressant, such as selective serotonin reuptake inhibitor [SSRI] or serotonin noradrenaline reuptake inhibitor [SNRI] or mirtazapine). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in sleep quality from pre-treatment assessed by the Pittsburgh Sleep Quality Index (PSQI) score at immediately post-treatment and 12 weeks post-treatment
This outcome measure evaluates the change in sleep quality in patients with major depressive disorder (MDD) and insomnia treated with Low-Dose Laser Acupuncture (LLA). The Pittsburgh Sleep Quality Index (PSQI) is used, with scores ranging from 0 to 21, where higher scores indicate poorer sleep quality.
Measured: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.
Secondary outcomes (8)
Changes in severity of depressive symptoms from pre-treatment assessed by Hamilton Depression Rating Scale (HAMD) score at immediately post-treatment and 12 weeks post-treatment
This outcome measure evaluates the impact of LLA on the severity of depressive symptoms in patients with MDD and insomnia. The Hamilton Depression Rating Scale (HAMD) is used, with scores ranging from 0 to 52, where higher scores indicate more severe depression symptoms.
Measured: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.
Changes in severity of insomnia from pre-treatment measure by Insomnia Severity Index (ISI) score at immediately post-treatment and 12 weeks post-treatment
This outcome measure assesses the impact of LLA on the change in severity of insomnia in patients with MDD and insomnia across time. The Insomnia Severity Index is used, with scores ranging from 0 to 28, where higher scores indicate more severe degree of insomnia.
Measured: Pre-treatment, immediately post-treatment and 12 weeks post-treatment
Changes in serum corticosterone levels from pre-treatment measure by Immunoassays at immediately post-treatment and 12 weeks post-treatment
This outcome measure examines the change in serum corticosterone levels in patients with MDD and insomnia treated with LLA. Corticosterone levels are measured in ng/mL, with higher levels typically associated with higher stress and worse outcomes.
Measured: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.
Changes in serum 5-Hydroxytryptamine (5-HT) levels from pre-treatment measure with Enzyme-Linked Immunosorbent Assay at immediately post-treatment and 12 weeks post-treatment
This outcome measure examines the change in serum 5-hydroxytryptamine (5-HT) levels in patients with MDD and insomnia treated with LLA. 5-HT levels are measured in ng/mL, with lower levels typically associated with worse outcomes in depression and insomnia.
Measured: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.
Changes in the incidence of treatment-emergent adverse events from pre-treatment assess as dropout rates at immediately post-treatment and 12 weeks post-treatment
This outcome measure assesses the incidence of treatment-emergent adverse events to determine the safety of LLA. It compares the dropout rates due to adverse effects among patients in the LLA, Sham Laser Acupuncture (SLA), and control groups.
Measured: Throughout the study duration (Pre-treatment through 12 weeks post-intervention)
Changes in the objective sleep patterns (total sleep time, sleep efficacy and number of awakenings) from pre-treatment assess by actigraphy to immediately post-treatment and 12 weeks post-treatment
Description: This outcome measure evaluates the change in objective sleep patterns in patients with MDD and insomnia treated with LLA. Actigraphy provides data on sleep parameters such as total sleep time, sleep efficiency, and number of awakenings.
Measured: Pre-treatment, immediately post-treatment and 12 weeks post-treatment
Monitoring of drug dose record (medication dosage and daily administration time) for any changes from pre-treatment and throughout the 12-week follow-up period of the study
The dose diary is a record book in which participants will record the medication name, dosage, and exact administration time daily from baseline from pre-treatment through the 12-week follow-up period of the study.
Measured: Throughout the study duration (Pre-treatment through 12 weeks post-intervention)
Monitoring of participant compliance to the intervention in the LLA and SLA groups from pre-treatment through the 12-week post-treatment follow-up
Participants' adherence to the intervention will be recorded in detail. For treatment absences, drop-outs, and loss to follow-up, the causes of non-compliance (such as reduced participation, aversion to the intervention, physical discomfort) will also be documented to ensure integrity and rigor throughout the study.
Measured: Throughout the study duration (Pre-treatment through 12 weeks post-intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2024
- Study start1 Dec 2025 (estimated)
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Major Depressive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mohammad Farris Iman Leong Bin Abdullah
- Sponsor type
- University, hospital or other
- Collaborators
- Henan Medical University
- Responsible party
- Sponsor-investigator, Mohammad Farris Iman Leong Bin Abdullah, Universiti Sains Malaysia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06443242
- Sponsor's protocol ID
- XYEFYLL-(Research)-2024-36
- Status last verified
- Sep 2025
- First submitted
- 13 May 2024
- Last updated
- 10 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual data will be made available after publication of the study's findings. The data will be uploaded in Figshare data repository after completion of the study.
Publications
Qiu Q, Yam MF, Yang W, Guo F, Liu C, Leong Bin Abdullah MFI, Yang S. Efficacy and safety of laser acupuncture for treating insomnia in major depressive disorder: study protocol for a randomized controlled trial. Front Psychiatry. 2025 Nov 20;16:1698773. doi: 10.3389/fpsyt.2025.1698773. eCollection 2025.
PubMed 41356687
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Low-dose Laser Acupuncture on Treating Insomnia Associated With Major Depressive Disorder: A Randomised Controlled Trial
- ClinicalTrials.gov ID
- NCT06443242
- Acronym / sponsor ID
- XYEFYLL-(Research)-2024-36
- Conditions
- Major Depressive Disorder, Insomnia
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Mohammad Farris Iman Leong Bin AbdullahUniversity, hospital or other
- Collaborators
- Henan Medical University
- Study start
- 1 Dec 2025 (estimated)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 5 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomized controlled trial is to assess the efficacy and safety of low-dose laser acupuncture (LLA) in alleviating insomnia symptoms among patients suffering from major depressive disorder.
The study seeks to answer the following questions:
- How effective is LLA in alleviating insomnia symptoms as compare with SLA and control subjects among patients with major depressive disorder across pre-treatment, mid-treatment and post-treatment assessment?
- How effective is LLA in alleviating depression symptoms as compare with SLA and control subjects among patients with major depressive disorder across pre-treatment, post-treatment and follow-up assessment?
- What role do CORT and 5-HT play in the co-occurrence and progression of insomnia and major depressive disorder, and how does LLA act on these mechanisms to provide relief?
- How does the safety and acceptability of LLA compare to traditional acupuncture in terms of eliminating discomfort and potential side effects? Researchers will compare the effects of LLA with sham laser acupuncture (SLA) and standard medication treatments to evaluate its efficacy and safety.
Participants involved in this study will:
Undergo 30 treatment sessions with LLA or SLA, five times a week for six weeks. Continue their usual pharmacological treatments for major depressive disorder. Participants will undergo comprehensive assessments at key points: pre-treatment, immediately post-treatment, and 12 weeks post-treatment. These evaluations will measure sleep quality and severity of insomnia indices, levels of depression and anxiety, and blood levels of CORT and 5-HT to assess the impact of LLA on insomnia symptoms and biochemical markers. Additionally, participant acceptance and the safety of the treatment will be monitored, including recording any adverse events and medication usage, to determine the effectiveness and safety of LLA in treating insomnia associated with major depressive disorder.
By focusing on these elements, the study aims to provide clear, actionable insights into the benefits and risks of LLA as a treatment option for insomnia associated with major depressive disorder, enhancing the current treatment landscape and patient outcomes.
Detailed description
This randomised controlled trial aims to explore the therapeutic potential of low-dose laser acupuncture (LLA) for treating insomnia in patients diagnosed with major depressive disorder. The study will investigate the physiological and psychological impacts of LLA in comparison with sham laser acupuncture (SLA) and standard pharmacological therapies.
Intervention Details:
LLA involves the application of a low-level laser to specific acupoints known to affect sleep and mood regulation. The technique mimics traditional acupuncture but uses laser light to stimulate these points without physical penetration of the skin, offering a non-invasive alternative with potentially fewer adverse effects. The primary acupoints targeted in this study include Baihui (GV20), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), and Taichong (LR3).
Study Phases:
The study will be structured into three key phases: pre-treatment, immediately post-treatment, and 12 weeks post-treatment. During the pre-treatment phase, baseline evaluations will be conducted to establish initial levels of insomnia and depressive symptoms in participants. The treatment phase will follow, lasting six weeks, with participants receiving five sessions per week. Subsequent assessments will occur immediately post-treatment to evaluate the immediate effects of the interventions, and again at 12 weeks post-treatment to assess the long-term outcomes.
Research Focus:
The study will particularly focus on the effectiveness of LLA in improving sleep quality as measured by validated scales and objective assessments like actigraphy, which monitors sleep-wake patterns. Additionally, the research will assess changes in psychological state and biochemical markers, which are critical in understanding the interaction between sleep disorders and depression. These measures will help ascertain whether LLA can alter the physiological pathways typically disrupted in major depressive disorder, potentially offering a new avenue for treatment that could complement or reduce the need for pharmacological intervention.
Innovation and Potential Impact:
By integrating a novel, non-invasive method such as LLA, the study could significantly impact the treatment strategies for insomnia in the context of major depressive disorder. This approach not only aims to reduce symptoms but also to enhance overall treatment tolerance and patient adherence, addressing key challenges in managing these interlinked conditions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Low-Dose Laser Acupuncture (LLA) Group | Experimental | Device: Low-Dose Laser Acupuncture (LLA)In the Low-Dose Laser Acupuncture (LLA) group, participants receive treatments using the xS-998D06 semiconductor laser acupoint therapeutic device from Nanjing Xiaosong Medical Instruments. This device operates at a wavelength of 780 nm and an output power of 5 mW. Each 20-minute session involves securing the device's probe to specific acupoints (Baihui, Yintang, Anmian, Shenmen, Neiguan, Sanyinjiao, and Taichong) using medical tape. Treatments occur daily for 5 consecutive days each week, with a two-day break, over a 6-week period. All participants, regardless of group assignment, will maintain their regular antidepressant regimen (patients with only one type of antidepressant, such as selective serotonin reuptake inhibitor [SSRI] or serotonin noradrenaline reuptake inhibitor [SNRI] or mirtazapine). |
| Sham Laser Acupuncture (SLA) Group | Sham comparator | Device: Sham Laser Acupuncture (SLA)Participants in the Sham Laser Acupuncture (SLA) group undergo a sham treatment involving the same procedure and acupoint targeting as the LLA group. The difference lies in the instrument probe being fixed to the acupoint but emitting a dummy laser, simulating the acupuncture experience without actual laser emission. All participants, regardless of group assignment, will maintain their regular antidepressant regimen (patients with only one type of antidepressant, such as selective serotonin reuptake inhibitor [SSRI] or serotonin noradrenaline reuptake inhibitor [SNRI] or mirtazapine). |
| Control Group | No intervention | –The control group, which serves as a non-intervention comparison, will continue their standard treatment regimen (patients with only one type of antidepressant, such as selective serotonin reuptake inhibitor [SSRI] or serotonin noradrenaline reuptake inhibitor [SNRI] or mirtazapine). |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Inpatients with a diagnosis of major depressive disorder (diagnosed according to the relevant diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders-V).
- Male or female, 18 to 60 years of age.
- Participants complaining of insomnia at initial screening.
- PSQI score over 7.
- HAMD score between 20 and 35.
Key exclusion criteria (6 listed)
- Individuals with a marked tendency towards suicide, as assessed by a specialist;
- Individuals previously diagnosed with schizophrenia, bipolar disorder, or other psychiatric disorders;
- Individuals with severe alcohol or drug abuse issues;
- Individuals with liver or kidney dysfunction, or with uncontrollable tumors or significant cerebrovascular diseases;
- Women who are pregnant or breastfeeding;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low-Dose Laser Acupuncture (LLA)The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep. | Device | Low-Dose Laser Acupuncture (LLA) Group |
| Sham Laser Acupuncture (SLA)Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment. | Device | Sham Laser Acupuncture (SLA) Group |
Primary outcome
Change in sleep quality from pre-treatment assessed by the Pittsburgh Sleep Quality Index (PSQI) score at immediately post-treatment and 12 weeks post-treatment
Time frame: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.
This outcome measure evaluates the change in sleep quality in patients with major depressive disorder (MDD) and insomnia treated with Low-Dose Laser Acupuncture (LLA). The Pittsburgh Sleep Quality Index (PSQI) is used, with scores ranging from 0 to 21, where higher scores indicate poorer sleep quality.
8 secondary outcomes
Changes in severity of depressive symptoms from pre-treatment assessed by Hamilton Depression Rating Scale (HAMD) score at immediately post-treatment and 12 weeks post-treatment
Time frame: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.
Changes in severity of insomnia from pre-treatment measure by Insomnia Severity Index (ISI) score at immediately post-treatment and 12 weeks post-treatment
Time frame: Pre-treatment, immediately post-treatment and 12 weeks post-treatment
Changes in serum corticosterone levels from pre-treatment measure by Immunoassays at immediately post-treatment and 12 weeks post-treatment
Time frame: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.
Changes in serum 5-Hydroxytryptamine (5-HT) levels from pre-treatment measure with Enzyme-Linked Immunosorbent Assay at immediately post-treatment and 12 weeks post-treatment
Time frame: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.
Changes in the incidence of treatment-emergent adverse events from pre-treatment assess as dropout rates at immediately post-treatment and 12 weeks post-treatment
Time frame: Throughout the study duration (Pre-treatment through 12 weeks post-intervention)
Changes in the objective sleep patterns (total sleep time, sleep efficacy and number of awakenings) from pre-treatment assess by actigraphy to immediately post-treatment and 12 weeks post-treatment
Time frame: Pre-treatment, immediately post-treatment and 12 weeks post-treatment
Monitoring of drug dose record (medication dosage and daily administration time) for any changes from pre-treatment and throughout the 12-week follow-up period of the study
Time frame: Throughout the study duration (Pre-treatment through 12 weeks post-intervention)
Monitoring of participant compliance to the intervention in the LLA and SLA groups from pre-treatment through the 12-week post-treatment follow-up
Time frame: Throughout the study duration (Pre-treatment through 12 weeks post-intervention)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2025.
- Derived from this study: PubMed 41356687Qiu Q, Yam MF, Yang W, Guo F, Liu C, Leong Bin Abdullah MFI, Yang S. Efficacy and safety of laser acupuncture for treating insomnia in major depressive disorder: study protocol for a randomized controlled trial. Front Psychiatry. 2025 Nov 20;16:1698773. doi: 10.3389/fpsyt.2025.1698773. eCollection 2025.
- Individual participant dataSharing planned: Yes. Anonymized individual data will be made available after publication of the study's findings. The data will be uploaded in Figshare data repository after completion of the study.
Related trials for Major Depressive Disorder
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
RecruitingPhase 4
Biomarker-Guided Antidepressant Selection
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Recruiting
Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
Major Depressive Disorder, Apathy
RecruitingObservational study
Student Precarity and Psychiatry
Depressive Disorder, Major, Generalized Anxiety Disorder
Not yet recruiting
Acute Intermittent Hypoxia Therapy for Depression
Major Depressive Disorder (MDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Low-Dose Laser Acupuncture (LLA) in people with Major Depressive Disorder and Insomnia, run by Mohammad Farris Iman Leong Bin Abdullah.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in sleep quality from pre-treatment assessed by the Pittsburgh Sleep Quality Index (PSQI) score at immediately post-treatment and 12 weeks post-treatment (time frame: Pre-treatment, immediately post-treatment and 12 weeks post-treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06443242, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025.